cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
2seventy Bio Inc
7 own
Current Price
$13.25
$0.37
(2.87%)
logo-tsvt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
502.33M
52-Week High
52-Week High
19.33
52-Week Low
52-Week Low
8.44
Average Volume
Average Volume
0.81M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization502.33M
icon52-Week High19.33
icon52-Week Low8.44
iconAverage Volume0.81M
iconDividend Yield--
iconP/E Ratio--
What does the 2seventy Bio Inc do?
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does 2seventy Bio Inc make?
News & Events about 2seventy Bio Inc.
Globe Newswire
12days ago
Milestone payment is related to the establishment of 2seventy bios strategic partnership with JW TherapeuticsPayment provides further validation of Medigenes end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: ...
Ticker Report
17days ago
2seventy bio (NASDAQ:TSVT Get Rating) had its price target reduced by SVB Leerink from $41.00 to $34.00 in a research report released on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. SVB Leerink also issued estimates for 2seventy bios Q4 2022 ...
Business Wire
24days ago
2seventy bio, Inc. (Nasdaq: TSVT) today announced an amendment to its collaboration with Regeneron that will facilitate an expanded and accelerated development plan for novel cell therapy-based combinations for solid tumors. The collaboration will leverage 2seventy bios unique cell therapy...
Zolmax
5 months ago
2seventy bio, Inc. (NASDAQ:TSVT Get Rating) insider Philip D. Gregory sold 2,407 shares of the companys stock in a transaction on Friday, August 5th. The stock was sold at an average price of $16.23, for a total value of $39,065.61. Following the sale, the insider now owns 104,388 shares of the ...
Frequently Asked Questions
Frequently Asked Questions
What is 2seventy Bio Inc share price today?
plus_minus_icon
Can Indians buy 2seventy Bio Inc shares?
plus_minus_icon
How can I buy 2seventy Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of 2seventy Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in 2seventy Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of 2seventy Bio Inc?
plus_minus_icon
What is today’s market capitalisation of 2seventy Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of 2seventy Bio Inc?
plus_minus_icon
What percentage is 2seventy Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is 2seventy Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.25
$0.37
(2.87%)
logo-tsvt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00